Video

Dr. Gandara Discusses the Future of Clinical Trial Designs

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

The paradigm for drug development is changing in lung cancer, though new concepts and themes can be applied to all cancers. Gandara says drug development has been ineffective to date for cancer therapies as a whole.

There remains a need for new ways of thinking, new strategies, and new clinical trial designs to increase the likelihood of benefit for patients with specific genomic abnormalities.

Currently, less than 5% of cancer drugs actually make it to patients, Gandara says. This also needs to be improved.

<<<

View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology

Related Videos
Cedric Pobel, MD
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.